文献速递肿瘤 PET/CT神经核医学

18F-FDOPA PET/CT 与 MR/CT 血管成像在临床复发性头颈部副神经节瘤中的头对头比较

Head-to-head comparison between 18F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-01-03

本研究回顾性评估16例头颈部副神经节瘤初治后随访期间出现临床症状疑似复发的患者,均行18F-FDOPA PET/CT及MRA(15例)或CTA(1例)。18F-FDOPA PET/CT与MRA/CTA在14例中结论一致、2例不一致,分别识别12例和10例疑似复发;PET/CT还额外检出2例同步原发HNPGL。作者建议当68Ga标记生长抑素类似物不可及时,对疑似复发的症状患者首选18F-FDOPA PET/CT。

要点

  • 18F-FDOPA PET/CT与MRA/CTA在14/16例中一致,2例不一致。
  • 18F-FDOPA PET/CT识别12例疑似复发,MRA/CTA识别10例。
  • PET/CT在2/16例中额外检出同步原发HNPGL。

核心结论

  • 18F-FDOPA PET/CT在HNPGL治疗后评估中高度敏感,观察者间可重复性优于MRA/CTA,并提供全身检查。
  • 作者建议当68Ga标记生长抑素类似物不可及时,对初治后疑似HNPGL复发的症状患者首选18F-FDOPA PET/CT作为诊断影像方法。

研究设计与样本

  • 回顾性评估16例连续患者,均为HNPGL初治后随访期间出现局部疼痛、耳鸣、吞咽困难、声音嘶哑、颅神经受累、耳聋或鼓膜后肿块。
  • 患者均行18F-FDOPA PET/CT及MRA(15例)或CTA(1例),两种方法先盲法评估后再行关联分析。
  • 无组织学确认的头颈部影像异常,基于放射科与核医学科医师共识及后续18F-FDOPA PET/CT和/或MRA视为真阳性。

主要发现

  • 18F-FDOPA PET/CT与MRA/CTA在14例中一致、2例不一致。
  • 18F-FDOPA PET/CT识别12例疑似复发性HNPGL,MRA/CTA识别10例。
  • 仅PET/CT诊断的2个病灶在随访中分别于29个月和17个月后经耳镜检查和MRA确认。
  • 18F-FDOPA PET/CT图像仅轻度受治疗后遗症影响,观察者间可重复性优于MRA/CTA。
  • 在2/16例中,18F-FDOPA PET/CT检出2个额外的同步原发HNPGL。

关键数值与推荐

  • 18F-FDOPA PET/CT与MRA/CTA一致14例、不一致2例。
  • 18F-FDOPA PET/CT识别12例疑似复发,MRA/CTA识别10例。
  • 仅PET/CT诊断的2个病灶分别于29个月和17个月后经耳镜检查和MRA确认。
  • 2/16例中PET/CT检出2个额外同步原发HNPGL。

临床怎么用

  • 作者建议当68Ga标记生长抑素类似物不可及时,对初治后疑似HNPGL复发的症状患者首选18F-FDOPA PET/CT作为诊断影像方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Head and neck paragangliomas (HNPGLs) can relapse after primary treatment. Optimal imaging protocols have not yet been established for posttreatment evaluation. The aim of the present study was to assess the diagnostic value of 18F-FDOPA PET/CT and MR/CT angiography (MRA/CTA) in HNPGL patients with clinical relapse during their follow-up. METHODS: Sixteen consecutive patients presenting with local pain, tinnitus, dysphagia, hoarse voice, cranial nerve involvement, deafness, or retrotympanic mass appearing during follow-up after the initial treatment of HNPGLs were retrospectively evaluated. Patients underwent both 18F-FDOPA PET/CT and MRA (15 patents) or CTA (1 patent). Both methods were first assessed under blinded conditions and afterwards correlated. Head and neck imaging abnormalities without histological confirmation were considered true-positive results based on a consensus between radiologists and nuclear physicians and on further 18F-FDOPA PET/CT and/or MRA. RESULTS: 18F-FDOPA PET/CT and MRA/CTA were concordant in 14 patients and in disagreement in 2 patients. 18F-FDOPA PET/CT and MRA/CTA identified, respectively, 12 and 10 presumed recurrent HNPGLs in 12 patients. The two lesions diagnosed by PET/CT only were confirmed during follow-up by otoscopic examination and MRA performed 29 and 17 months later. 18F-FDOPA PET/CT images were only slightly influenced by the posttreatment sequelae, showing a better interobserver reproducibility than MRA/CTA. Finally, in 2 of the 16 studied patients, 18F-FDOPA PET/CT detected two additional synchronous primary HNPGLs. CONCLUSION: 18F-FDOPA PET/CT is highly sensitive in posttreatment evaluation of patients with HNPGLs, and also offers better interobserver reproducibility than MRA/CTA and whole-body examination. We therefore suggest that 18F-FDOPA PET/CT is performed as the first diagnostic imaging modality in symptomatic patients with suspicion of HNPGL relapse after primary treatment when 68Ga-labeled somatostatin analogues are not available.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Heimburger C, Veillon F, Taïeb D, et al. Head-to-head comparison between 18F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2017. PMID: 28050631. doi:10.1007/s00259-016-3605-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。